Polyethylene glycol-interferon: current status in hepatitis C virus therapy

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C infection (HCV) treatment with interferon (IFN)-alpha and ribavirin yields suboptimal response rates (40-45%), particularly for specific patient groups.
• Significant side-effects of conventional therapy often necessitate dose reductions or discontinuation, further compromising treatment efficacy.
• HCV genotype 1, high viral load, and advanced liver fibrosis are associated with poorer treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of modified interferon therapies for chronic hepatitis C.
• To establish an improved standard of care for chronic hepatitis C infection.

Main Methods:

• Development of modified interferon through polyethylene glycol (PEG) conjugation to IFN-alpha.
• Administration of PEG-IFN as monotherapy and in combination with ribavirin.
• Assessment of sustained virological response rates and safety profiles.

Main Results:

• PEG-IFN monotherapy demonstrated twice the efficacy of conventional IFN-alpha.
• Combination therapy with PEG-IFN and ribavirin achieved sustained virological response rates of 54-56%.
• PEGylation extended IFN half-life, enabling once-weekly dosing and enhancing antiviral activity without compromising safety.

Conclusions:

• Polyethylene glycol-conjugated interferon (PEG-IFN) in combination with ribavirin represents a new standard therapy for chronic hepatitis C.
• This combination significantly improves sustained virological response rates compared to conventional therapies.
• PEG-IFN offers a more convenient dosing schedule and improved efficacy for a broader range of patients.